Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660773 | 0.83 | GRM4 (0.51) | ALDH1A1TDP1GRM4EGFRTRPA1 | |
| SCHEMBL2661213 | 0.80 | GRM4 (0.57) | ALDH1A1TDP1GRM4ADRA2AAURKA | |
| SCHEMBL2668093 | 0.77 | GRM4 (0.47) | ALDH1A1TDP1GRM4PLA2G7ADRA2A | |
| SCHEMBL11698454 | 0.74 | KIF11 (0.42) | ALDH1A1TDP1EGFRTRPA1KIF11 | |
| SCHEMBL2660583 | 0.72 | GRM4 (0.54) | ALDH1A1TDP1GRM4TRPA1KIF11 | |
| SCHEMBL4796082 | 0.71 | FADS1 (0.61) | GRM4EGFRTRPA1AURKB | |
| SCHEMBL5583098 | 0.69 | KIF11 (0.38) | ALDH1A1EGFRTRPA1KIF11KDM4E | |
| SCHEMBL2661233 | 0.67 | CHEK1 (0.55) | ALDH1A1KIF11KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL13122112 | 0.67 | KIF11 (0.47) | ALDH1A1EGFRTRPA1KIF11KDM4E | |
| SCHEMBL786506 | 0.67 | USP1 (0.63) | ALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966152-A2 | GLUCOKINASE ACTIVATORS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-10 | — | — | EP | claimed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | claimed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | claimed |
| EP-1966152-A2 | GLUCOKINASE ACTIVATORS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. | 2007-10-18 | — | — | US | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075847-A2 | GLUCOKINASE ACTIVATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244169-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | ALDH1A1 1527/4885TDP1 2852/4885GRM4 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.